Gossamer Bio Targets NDA Filing for Seralutinib in September 2026 with Potential Approval by Q3 2027

Gossamer Bio (NASDAQ:GOSS) plans to file a New Drug Application (NDA) for seralutinib in September 2026, aiming for potential FDA approval as early as the third quarter of 2027. The company's CEO highlighted mixed statistical results but clinically meaningful outcomes from its PROSERA trial.

By SA Transcript Insights Editor, SA News Editor · Seeking Alpha · May 18, 2026, 22:11 UTC

Tickers: $GOSS

Topics: biotech earnings call pharmaceuticals PROSERA drug

Read the full article at Seeking Alpha

More World news

Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC
NYSE Sees $500 Billion in Market Cap Transfers from Competitors in 2026 PR Newswire · November 12, 2026, 17:45 UTC
Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC
Suburban Propane Reports Fiscal 2026 Results with Increased Adjusted EBITDA and RNG Growth Motley Fool · November 12, 2026, 17:40 UTC
Altimmune Reports Third Quarter 2026 Financial Results Amid Increased R&D Spending Motley Fool · November 12, 2026, 17:40 UTC
CorMedix Reports Q3 2026 Results Amid DefenCath Pricing Transition and Heron Therapeutics Acquisition Plans Motley Fool · November 12, 2026, 17:40 UTC
NUGL Reports Third Quarter Net Income of $0.19 Million and Revenue of $1.04 Million Seeking Alpha · November 12, 2026, 17:38 UTC
Allstate Announces Quarterly Dividend of $1.08 Per Share PR Newswire · November 12, 2026, 17:38 UTC
Stephanie Link Shifts AI Allocation from Nvidia to Micron Technology Following CEO Resignation CNBC · November 12, 2026, 17:37 UTC
Boyd Group Reports 28% Revenue Growth and $90 Million in Cost Savings for Q3 2026 Motley Fool · November 12, 2026, 17:33 UTC